Download PDF
Semin Thromb Hemost 2013; 39(07): 816-833
DOI: 10.1055/s-0033-1356573
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Problems and Solutions in Laboratory Testing for Hemophilia

Emmanuel J. Favaloro
1   Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Pathology West, Westmead Hospital, Westmead, New South Wales, Australia
,
Piet Meijer
2   ECAT Foundation, Dobbeweg 1, Voorschoten, The Netherlands
,
Ian Jennings
3   NEQAS UK Coagulation, Sheffield, United Kingdom
,
John Sioufi
4   RCPAQAP Haematology, St Leonards, New South Wales, Australia
,
Roslyn A. Bonar
4   RCPAQAP Haematology, St Leonards, New South Wales, Australia
,
Dianne P. Kitchen
2   ECAT Foundation, Dobbeweg 1, Voorschoten, The Netherlands
,
Geoffrey Kershaw
5   Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
,
Giuseppe Lippi
6   Department of Pathology and Laboratory Medicine, Laboratory of Clinical Chemistry and Hematology, Academic Hospital of Parma, Parma, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
11 September 2013 (online)

    Permissions and Reprints

Corrected by:

Problems and Solutions in Laboratory Testing for HemophiliaSemin Thromb Hemost 2014; 40(01): 135-135
DOI: 10.1055/s-0033-1360721

Abstract

A diagnosis of hemophilia A or hemophilia B begins with clinical assessment of the patient and is facilitated by laboratory testing. The influence of the latter on a diagnosis of hemophilia A or hemophilia B is clear—a diagnosis cannot be made without laboratory confirmation of a deficiency of factor FVIII (FVIII) or factor IX (FIX), respectively. Moreover, the degree of hemophilia severity is specifically characterized by laboratory test results. In turn, patient management, including choice and application of therapies, is influenced by the diagnosis, as well as by identification of respective disease severity. An incorrect diagnosis may lead to inappropriate management and unnecessary therapy, and thus to adverse outcomes. Moreover, identification of factor inhibitors in hemophilia will lead to additional and differential treatments, and incorrect identification of inhibitors or inhibitor levels may also lead to inappropriate management. Problems in hemophilia diagnosis or inhibitor detection can occur at any stage in the clinical diagnosis/laboratory interface, from the “pre-preanalytical” to “preanalytical” to “analytical” to “postanalytical” to “post-postanalytical.” This report outlines the various problems in laboratory testing for hemophilia and provides various strategies or solutions to overcome these challenges. Although some outlined solutions are specific to the potential errors related to hemophilia, others are general in nature and can be applied to other areas of laboratory hemostasis. Key to improvement in this area is adoption of best practice by all involved, including clinicians, phlebotomists, and laboratories. Also key is the recognition that such errors may occur, and thus that clinicians should assess laboratory test results in the context of their patient's clinical history and follow-up any potential errors, thus avoid misdiagnoses, by requesting repeat testing on a fresh sample.

Keywords

hemophilia - laboratory testing - preanalytical - analytical - quality - diagnostic practice
 

  • References

  • 1 Santagostino E, Fasulo MR. Hemophilia A and hemophilia B: different types of diseases?. Semin Thromb Hemost 2013; 39 (7) 697-701
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Pavlova A, Oldenburg J. Defining severity of hemophilia: more than factor levels. Semin Thromb Hemost 2013; 39 (7) 702-710
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Tay L, Duncan E, Singhal D , et al. Twelve years of experience of acquired hemophilia A: trials and tribulations in South Australia. Semin Thromb Hemost 2009; 35 (8) 769-777
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Coppola A, Favaloro EJ, Tufano A, Di Minno MN, Cerbone AM, Franchini M. Acquired inhibitors of coagulation factors: part I-acquired hemophilia A. Semin Thromb Hemost 2012; 38 (5) 433-446
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Webert KE. Acquired hemophilia A. Semin Thromb Hemost 2012; 38 (7) 735-741
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Franchini M, Lippi G. Acquired hemophilia A. Adv Clin Chem 2011; 54: 71-80
    PubMedGoogle Scholar
  • 7 Franchini M, Zaffanello M, Lippi G. Acquired hemophilia in pediatrics: a systematic review. Pediatr Blood Cancer 2010; 55 (4) 606-611
    CrossrefPubMedGoogle Scholar
  • 8 Franchini M, Targher G, Montagnana M, Lippi G. Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clin Chim Acta 2008; 395 (1-2) 14-18
    CrossrefPubMedGoogle Scholar
  • 9 White II GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J ; Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85 (3) 560
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Preston FE, Kitchen S, Jennings I, Woods TA, Makris M. SSC/ISTH classification of hemophilia A: can hemophilia center laboratories achieve the new criteria?. J Thromb Haemost 2004; 2 (2) 271-274
    CrossrefPubMedGoogle Scholar
  • 11 Mannucci PM, Franchini M. Is haemophilia B less severe than haemophilia A?. Haemophilia 2013; 19 (4) 499-502
    CrossrefPubMedGoogle Scholar
  • 12 Santoro C, Baldacci E, Mercanti C, Mazzucconi MG. Tailored versus standard dose prophylaxis in children with hemophilia A. Semin Thromb Hemost 2013; 39 (7) 711-722
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Di Perna C, Riccardi F, Franchini M, Rivolta GF, Pattacini C, Tagliaferri A. Clinical efficacy and determinants of response to treatment with desmopressin in mild hemophilia A. Semin Thromb Hemost 2013; 39 (7) 732-739
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Lippi G, Favaloro EJ, Franchini M. Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT. J Thromb Thrombolysis 2012; 34 (3) 360-366
    CrossrefPubMedGoogle Scholar
  • 15 Verbruggen B, Meijer P, Novákova I, Van Heerde W. Diagnosis of factor VIII deficiency. Haemophilia 2008; 14 (Suppl. 03) 76-82
    CrossrefPubMedGoogle Scholar
  • 16 Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus NovoSeven in hemophilia patients with inhibitors. Semin Thromb Hemost 2013; 39 (7) 772-778
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Persson E, Olsen OH, Bjørn SE, Ezban M. Vatreptacog alfa from conception to clinical proof of concept. Semin Thromb Hemost 2012; 38 (3) 274-281
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Lippi G, Franchini M, Montagnana M, Salvagno GL, Poli G, Guidi GC. Quality and reliability of routine coagulation testing: can we trust that sample?. Blood Coagul Fibrinolysis 2006; 17 (7) 513-519
    CrossrefPubMedGoogle Scholar
  • 19 Favaloro EJ, , (Adcock) Funk DM, Lippi G. Preanalytical variables in coagulation testing associated to diagnostic errors in hemostasis. Lab Med 2012; 43: 54-60
    PubMedGoogle Scholar
  • 20 Plebani M, Favaloro EJ, Lippi G. Patient safety and quality in laboratory and hemostasis testing: a renewed loop?. Semin Thromb Hemost 2012; 38 (6) 553-558
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Lippi G, Simundic AM. Laboratory networking and sample quality: a still relevant issue for patient safety. Clin Chem Lab Med 2012; 50 (10) 1703-1705
    PubMedGoogle Scholar
  • 22 Bonar R, Favaloro EJ, Adcock D. Quality in coagulation and haemostasis testing. Biochem Med 2010; 20 (2) 184-199
    PubMedGoogle Scholar
  • 23 Schulman S, Eelde A, Holmström M, Ståhlberg G, Odeberg J, Blombäck M. Validation of a composite score for clinical severity of hemophilia. J Thromb Haemost 2008; 6 (7) 1113-1121
    CrossrefPubMedGoogle Scholar
  • 24 Vyas S, Enockson C, Hernandez L, Valentino LA. Towards personalizing haemophilia care: using the Haemophilia Severity Score to assess 178 patients in a single institution. Haemophilia 2013; ; (e-pub ahead of print). doi: 10.1111/hae.12227
    PubMedGoogle Scholar
  • 25 Lippi G, Fostini R, Guidi GC. Quality improvement in laboratory medicine: extra-analytical issues. Clin Lab Med 2008; 28 (2) 285-294, vii
    CrossrefPubMedGoogle Scholar
  • 26 Lippi G, Blanckaert N, Bonini P , et al. Causes, consequences, detection, and prevention of identification errors in laboratory diagnostics. Clin Chem Lab Med 2009; 47 (2) 143-153
    CrossrefPubMedGoogle Scholar
  • 27 Lippi G, Salvagno GL, Montagnana M, Lima-Oliveira G, Guidi GC, Favaloro EJ. Quality standards for sample collection in coagulation testing. Semin Thromb Hemost 2012; 38 (6) 565-575
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Adcock Funk DM, Lippi G, Favaloro EJ. Quality standards for sample processing, transportation, and storage in hemostasis testing. Semin Thromb Hemost 2012; 38 (6) 576-585
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Xu J, Yu Z, Zhang L, Ruan C, Yang R. Diagnosis and management of von Willebrand disease in China. Semin Thromb Hemost 2011; 37 (5) 607-614
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Favaloro EJ, Mohammed S, Koutts J. Identification and prevalence of von Willebrand disease type 2N (Normandy) in Australia. Blood Coagul Fibrinolysis 2009; 20 (8) 706-714
    CrossrefPubMedGoogle Scholar
  • 31 Favaloro EJ. Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost 2011; 37 (5) 440-455
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ. Laboratory diagnosis and molecular classification of von Willebrand disease. Acta Haematol 2009; 121 (2-3) 71-84
    CrossrefPubMedGoogle Scholar
  • 33 Michiels JJ, Gadisseur A, Vangenegten I, Schroyens W, Berneman Z. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1. Acta Haematol 2009; 121 (2-3) 119-127
    CrossrefPubMedGoogle Scholar
  • 34 Gaucher C, Jorieux S, Mercier B, Oufkir D, Mazurier C. The “Normandy” variant of von Willebrand disease: characterization of a point mutation in the von Willebrand factor gene. Blood 1991; 77 (9) 1937-1941
    PubMedGoogle Scholar
  • 35 Spreafico M, Peyvandi F. Combined factor V and factor VIII deficiency. Semin Thromb Hemost 2009; 35 (4) 390-399
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Zheng C, Zhang B. Combined deficiency of coagulation factors V and VIII: an update. Semin Thromb Hemost 2013; 39 (6) 613-620
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Peyvandi F, Favaloro EJ. Rare bleeding disorders. Semin Thromb Hemost 2009; 35 (4) 345-347
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Page DA. Change designation of clotting factors to Arabic numerals. J Thromb Haemost 2009; 7 (9) 1599
    CrossrefPubMedGoogle Scholar
  • 39 Favaloro EJ, Lippi G. Problems in laboratory testing: hemophilia and beyond. J Thromb Haemost 2010; 8 (5) 1119-1120
    PubMedGoogle Scholar
  • 40 Favaloro EJ, Lippi G. The new oral anticoagulants and the future of haemostasis laboratory testing. Biochem Med (Zagreb) 2012; 22 (3) 329-341
    PubMedGoogle Scholar
  • 41 Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology 2011; 43 (7) 682-692
    CrossrefPubMedGoogle Scholar
  • 42 Cooper PC, Goodeve AC, Beauchamp NJ. Quality in molecular biology testing for inherited thrombophilia disorders. Semin Thromb Hemost 2012; 38 (6) 600-612
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Favaloro EJ, Bonar R, Duncan E , et al; RCPA QAP in Haematology Haemostasis Committee. Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation. Thromb Haemost 2006; 96 (1) 73-78
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Favaloro EJ, Bonar R, Duncan E , et al. Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation. Pathology 2007; 39 (5) 504-511
    CrossrefPubMedGoogle Scholar
  • 45 Halbmayer WM, Weigel G, Quehenberger P , et al. Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med 2012; 50 (9) 1601-1605
    PubMedGoogle Scholar
  • 46 Asmis LM, Alberio L, Angelillo-Scherrer A , et al. Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res 2012; 129 (4) 492-498
    CrossrefPubMedGoogle Scholar
  • 47 Hillarp A, Baghaei F, Fagerberg Blixter I , et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011; 9 (1) 133-139
    CrossrefPubMedGoogle Scholar
  • 48 van Ryn J, Stangier J, Haertter S , et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103 (6) 1116-1127
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Favaloro EJ, Soltani S, McDonald J, Grezchnik E, Easton L. Cross-laboratory audit of normal reference ranges and assessment of ABO blood group, gender and age on detected levels of plasma coagulation factors. Blood Coagul Fibrinolysis 2005; 16 (8) 597-605
    CrossrefPubMedGoogle Scholar
  • 50 Lippi G, Salvagno GL, Adcock DM, Gelati M, Guidi GC, Favaloro EJ. Right or wrong sample received for coagulation testing? Tentative algorithms for detection of an incorrect type of sample. Int J Lab Hematol 2010; 32 (1 Pt 2) 132-138
    CrossrefPubMedGoogle Scholar
  • 51 Lippi G, Simundic AM. Laboratory networking and sample quality: a still relevant issue for patient safety. Clin Chem Lab Med 2012; 50 (10) 1703-1705
    PubMedGoogle Scholar
  • 52 Lima-Oliveira G, Lippi G, Salvagno GL, Montagnana M, Picheth G, Guidi GC. Incorrect order of draw could be mitigate the patient safety: a phlebotomy management case report. Biochem Med (Zagreb) 2013; 23 (2) 218-223
    PubMedGoogle Scholar
  • 53 Salvagno GL, Lima-Oliveira G, Brocco G, Danese E, Guidi GC, Lippi G. The order of draw: myth or science?. Clin Chem Lab Med 2013; 1–5: 1-5 10.1515/cclm-2013-0412 [Epub ahead of print].)
    PubMedGoogle Scholar
  • 54 Lippi G, Salvagno GL, Montagnana M, Guidi GC. Short-term venous stasis influences routine coagulation testing. Blood Coagul Fibrinolysis 2005; 16 (6) 453-458
    CrossrefPubMedGoogle Scholar
  • 55 Lippi G, Plebani M, Favaloro EJ. Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia. Semin Thromb Hemost 2013; 39 (3) 258-266
    Article in Thieme ConnectPubMedGoogle Scholar
  • 56 Lippi G, Salvagno GL, Montagnana M, Guidi GC. Influence of primary sample mixing on routine coagulation testing. Blood Coagul Fibrinolysis 2007; 18 (7) 709-711
    PubMedGoogle Scholar
  • 57 Lippi G, Plebani M. Primary blood tubes mixing: time for updated recommendations. Clin Chem Lab Med 2012; 50 (4) 599-600
    CrossrefPubMedGoogle Scholar
  • 58 Lippi G, Lima-Oliveira G, Nazer SC , et al. Suitability of a transport box for blood sample shipment over a long period. Clin Biochem 2011; 44 (12) 1028-1029
    CrossrefPubMedGoogle Scholar
  • 59 Salvagno GL, Lippi G, Montagnana M, Franchini M, Poli G, Guidi GC. Influence of temperature and time before centrifugation of specimens for routine coagulation testing. Int J Lab Hematol 2009; 31 (4) 462-467
    CrossrefPubMedGoogle Scholar
  • 60 Lippi G, Salvagno GL, Montagnana M, Poli G, Guidi GC. Influence of centrifuge temperature on routine coagulation testing. Clin Chem 2006; 52 (3) 537-538
    CrossrefPubMedGoogle Scholar
  • 61 Lippi G, Salvagno GL, Montagnana M, Manzato F, Guidi GC. Influence of the centrifuge time of primary plasma tubes on routine coagulation testing. Blood Coagul Fibrinolysis 2007; 18 (5) 525-528
    CrossrefPubMedGoogle Scholar
  • 62 Lippi G, Rossi R, Ippolito L, Zobbi V, Azzi D, Pipitone S, Favaloro EJ, Adcock Funk DM. Influence of residual platelet count on routine coagulation, factor VIII, and factor IX testing in postfreeze-thaw samples. Semin Thromb Hemost 2013; 39 (7) 834-839
    Article in Thieme ConnectPubMedGoogle Scholar
  • 63 Lippi G, Salvagno GL, Bassi A, Montagnana M, Poli G, Guidi GC. Dishomogeneous separation of citrated plasma in primary collection tubes for routine coagulation testing. Blood Coagul Fibrinolysis 2008; 19 (4) 330-332
    CrossrefPubMedGoogle Scholar
  • 64 Favaloro EJ. Standardization, regulation, quality assurance and emerging technologies in hemostasis: issues, controversies, benefits, and limitations. Semin Thromb Hemost 2007; 33 (3) 290-297
    Article in Thieme ConnectPubMedGoogle Scholar
  • 65 Olson JD, Preston FE, Nichols WL. External quality assurance in thrombosis and hemostasis: an international perspective. Semin Thromb Hemost 2007; 33 (3) 220-225
    Article in Thieme ConnectPubMedGoogle Scholar
  • 66 Favaloro EJ, Bonar R, Marsden K. Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification. Clin Lab Sci 2008; 21 (3) 178-183
    PubMedGoogle Scholar
  • 67 Jennings I, Kitchen DP, Kitchen S, Woods TA, Walker ID. Investigation of a prolonged APTT. Different approaches taken by laboratories to achieve the same diagnosis. Int J Lab Hematol 2013; 35 (2) 177-182
    CrossrefPubMedGoogle Scholar
  • 68 Kershaw G, Orellana D. Mixing tests: diagnostic aides in the investigation of prolonged prothrombin times and activated partial thromboplastin times. Semin Thromb Hemost 2013; 39 (3) 283-290
    Article in Thieme ConnectPubMedGoogle Scholar
  • 69 Kershaw G, Favaloro EJ. Laboratory identification of factor inhibitors: an update. Pathology 2012; 44 (4) 293-302
    CrossrefPubMedGoogle Scholar
  • 70 Favaloro EJ, Bonar R, Kershaw G, Duncan E, Sioufi J, Marsden K. Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors. Semin Thromb Hemost 2009; 35 (8) 794-805
    Article in Thieme ConnectPubMedGoogle Scholar
  • 71 Favaloro EJ, Bonar R, Kershaw G, Mohammed S, Duncan E, Marsden K ; RCPA Haematology QAP Haemostasis Committee. Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia. Haemophilia 2010; 16 (4) 662-670
    PubMedGoogle Scholar
  • 72 Bonar RA, Favaloro EJ, Marsden K. External quality assessment of factor VIII inhibitor assays. Semin Thromb Hemost 2013; 39 (3) 320-326
    Article in Thieme ConnectPubMedGoogle Scholar
  • 73 Meijer P, Verbruggen B. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation. Semin Thromb Hemost 2009; 35 (8) 786-793
    Article in Thieme ConnectPubMedGoogle Scholar
  • 74 Kitchen S, Jennings I, Preston FE, Kitchen DP, Woods TA, Walker ID. Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation. Semin Thromb Hemost 2009; 35 (8) 778-785
    Article in Thieme ConnectPubMedGoogle Scholar
  • 75 Dardikh M, Meijer P, van der Meer F, Favaloro EJ, Verbruggen B. Acquired functional coagulation inhibitors: review on epidemiology, results of a wet-workshop on laboratory detection, and implications for quality of inhibitor diagnosis. Semin Thromb Hemost 2012; 38 (6) 613-621
    Article in Thieme ConnectPubMedGoogle Scholar
  • 76 Verbruggen B, Dardikh M, Polenewen R, van Duren C, Meijer P. The factor VIII inhibitor assays can be standardized: results of a workshop. J Thromb Haemost 2011; 9 (10) 2003-2008
    CrossrefPubMedGoogle Scholar
  • 77 Lippi G, Franchini M, Favaloro EJ. One-stage clotting versus chromogenic assays for assessing recombinant factor VIII: two faces of a haemostasis coin. Blood Coagul Fibrinolysis 2009; 20 (1) 1-3
    CrossrefPubMedGoogle Scholar
  • 78 Duncan EM, Rodgers SE, McRae SJ. Diagnostic testing for mild hemophilia a in patients with discrepant one-stage, two-stage, and chromogenic factor VIII:C assays. Semin Thromb Hemost 2013; 39 (3) 272-282
    Article in Thieme ConnectPubMedGoogle Scholar
  • 79 Bowyer AE, van Veen JJ, Goodeve A, Kitchen S, Makris M. Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A. Haematologica 2013; ; doi: 10.3324/haematol.2013.088088
    PubMedGoogle Scholar
  • 80 Lippi G, Favaloro EJ. Activated partial thromboplastin time: new tricks for an old dogma. Semin Thromb Hemost 2008; 34 (7) 604-611
    Article in Thieme ConnectPubMedGoogle Scholar
  • 81 Watson HG, Greaves M. Can we predict bleeding?. Semin Thromb Hemost 2008; 34 (1) 97-103
    Article in Thieme ConnectPubMedGoogle Scholar
  • 82 Hayward CP, Moffat KA, Liu Y. Laboratory investigations for bleeding disorders. Semin Thromb Hemost 2012; 38 (7) 742-752
    Article in Thieme ConnectPubMedGoogle Scholar
  • 83 Lippi G, Mengoni A, Manzato F. Sensitivity of two commercial reagents for prothrombin time and activated partial thromboplastin time to isolate coagulation factor deficiencies. Eur J Lab Med 1999; 7: 61-65
    PubMedGoogle Scholar
  • 84 Bowyer A, Kitchen S, Makris M. The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies. Int J Lab Hematol 2011; 33 (2) 154-158
    CrossrefPubMedGoogle Scholar
  • 85 Salvagno GL, Berntorp E. Thrombin generation testing for monitoring hemophilia treatment: a clinical perspective. Semin Thromb Hemost 2010; 36 (7) 780-790
    Article in Thieme ConnectPubMedGoogle Scholar
  • 86 Favaloro EJ, Lippi G. Coagulation update: what's new in hemostasis testing?. Thromb Res 2011; 127 (Suppl. 02) S13-S16
    PubMedGoogle Scholar
  • 87 Wegner J, Popovsky MA. Clinical utility of thromboelastography: one size does not fit all. Semin Thromb Hemost 2010; 36 (7) 699-706
    Article in Thieme ConnectPubMedGoogle Scholar
  • 88 Dargaud Y, Sorensen B, Shima M, Hayward C, Srivastava A, Negrier C. Global haemostasis and point of care testing. Haemophilia 2012; 18 (Suppl. 04) 81-88
    CrossrefPubMedGoogle Scholar
  • 89 Livnat T, Martinowitz U, Azar-Avivi S , et al. Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors - a thrombin generation-guided pilot study. Haemophilia (e-pub ahead of print) 2013; doi: 10.1111/hae.12181
    PubMedGoogle Scholar
  • 90 Tarandovskiy ID, Balandina AN, Kopylov KG , et al. Investigation of the phenotype heterogeneity in severe hemophilia A using thromboelastography, thrombin generation, and thrombodynamics. Thromb Res 2013; 131 (6) e274-e280
    CrossrefPubMedGoogle Scholar
  • 91 Al Hawaj MA, Martin EJ, Venitz J , et al. Monitoring rFVIII prophylaxis dosing using global haemostasis assays. Haemophilia 2013; 19 (3) 409-414
    CrossrefPubMedGoogle Scholar
  • 92 Young G, Sørensen B, Dargaud Y, Negrier C, Brummel-Ziedins K, Key NS. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood 2013; 121 (11) 1944-1950
    CrossrefPubMedGoogle Scholar
  • 93 Ay Y, Balkan C, Karapinar DY, Akin M, Bilenoğlu B, Kavakli K. Feasibility of using thrombin generation assay (TGA) for monitoring of haemostasis during supplementation therapy in haemophilic patients without inhibitors. Haemophilia 2012; 18 (6) 911-916
    CrossrefPubMedGoogle Scholar
  • 94 Kluft C, Meijer P. External quality assessment for thrombin generation tests: an exploration. Semin Thromb Hemost 2010; 36 (7) 791-796
    Article in Thieme ConnectPubMedGoogle Scholar
  • 95 Kitchen DP, Kitchen S, Jennings I, Woods T, Walker I. Quality assurance and quality control of thrombelastography and rotational Thromboelastometry: the UK NEQAS for blood coagulation experience. Semin Thromb Hemost 2010; 36 (7) 757-763
    Article in Thieme ConnectPubMedGoogle Scholar
  • 96 Kershaw G, Jayakodi D, Dunkley S. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center. Semin Thromb Hemost 2009; 35 (8) 760-768
    Article in Thieme ConnectPubMedGoogle Scholar